Hypersensitivity pneumonitis

Global Progressive Pulmonary Fibrosis Market to 2032 - Insights, Epidemiology and Forecasts - ResearchAndMarkets.com

Retrieved on: 
Monday, October 24, 2022
Managed Care, Pharmaceutical, Health, Cardiology, Hypersensitivity pneumonitis, Connective tissue, Interstitial lung disease, Rheumatoid arthritis, MOA, PPF, Vicki Belo, Degenerative disease, Review, SWOT, Prevalence, Pneumonia, Idiopathic interstitial pneumonia, Report, Phenotype, Research, Mortality, Idiopathic disease, III, World Intellectual Property Day, Sarcoidosis, Asbestos, ILD, United Kingdom, Classification, BI, USD, ROA, Management, Renewable energy, Aluminium, Pharmaceutical industry, Vaccine, Epidemiology

The "Progressive Pulmonary Fibrosis (PPF) - Market Insights, Epidemiology, and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Progressive Pulmonary Fibrosis (PPF) - Market Insights, Epidemiology, and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.
  • This report deliver an in-depth understanding of the Progressive pulmonary fibrosis (PPF), historical and forecasted epidemiology as well as the Progressive pulmonary fibrosis (PPF) market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
  • The Progressive pulmonary fibrosis (PPF) market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Progressive pulmonary fibrosis (PPF) market size from 2019 to 2032.
  • Major players are involved in developing therapies for Progressive pulmonary fibrosis (PPF) s. The launch of emerging therapies will significantly impact the Progressive pulmonary fibrosis (PPF) market.

Cyclo Therapeutics Announces Publication of Phase 1 Data for Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C1 (NPC1)

Retrieved on: 
Tuesday, October 18, 2022
Biotechnology, Pharmaceutical, Health, Clinical Trials, Niemann–Pick disease, Niemann–Pick disease, type C, Science, Traffic barrier, Priority review, Protocol, Expanded access, Death, Journal, Half-life, Molecular genetics, Biomarker, Intravenous therapy, Lung, Plasma, Therapy, PPCS, Spleen, Serum, Company, Hearing loss, Cerebrospinal fluid, Hypersensitivity pneumonitis, C1, NPC1, Neurology, Manuscript, Central nervous system, Risk, Metabolism, CSF, Diagnosis, Security (finance), Cell, Filipin, NPC, Lists of diseases, U.S. Securities and Exchange Commission, CNS, Neurodegeneration, Week, CYTH, Form 10-K, Disease, Cholesterol, Patient, Nasdaq, Molecular Genetics and Metabolism, Learning, Society, Adult, Safety, Liver, Brain, Pharmaceutical industry, MD, EU

The data seen to-date provide support for the capacity of Trappsol Cyclo to stabilize disease progression with intravenous infusions in NPC.

Key Points: 
  • The data seen to-date provide support for the capacity of Trappsol Cyclo to stabilize disease progression with intravenous infusions in NPC.
  • In these Phase 1 data, Trappsol Cyclo cleared cholesterol from the liver and improved peripheral and central nervous system biomarkers of cholesterol homeostasis.
  • I am pleased with the progress weve made and look forward to learning more about the full potential of Trappsol Cyclo for the treatment of NPC.
  • Cyclo Therapeutics continues to advance enrollment in its ongoing pivotal Phase 3 study, TransportNPC evaluating Trappsol Cyclo for the treatment of NPC1.

Global Respiratory Partnering Directory/Report 2021: Comprehensive Access to 850+ Deal Records - Deal Trends, Players and Financials - ResearchAndMarkets.com

Retrieved on: 
Monday, March 14, 2022
General Health, Pharmaceutical, Health, Other Health, Shortness of breath, Hypersensitivity pneumonitis, Pulmonary hypertension, Contract, Research, Finance, Nasal congestion, Bronchitis, Asthma, Chronic obstructive pulmonary disease, Acute respiratory distress syndrome, Respiratory disease, Players, Respiratory tract infection, Silicosis, Idiopathic pulmonary fibrosis, Technology, Sarcoidosis, Coalworker's pneumoconiosis, Pulmonary embolism, Chest pain, Occupational lung disease, Allergic rhinitis, Sales, Poultry, Asbestosis, Sinusitis, Cough, Global, Snoring, Pneumonia

The "Global Respiratory Partnering 2010-2021: Deal Trends, Players and Financials" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Respiratory Partnering 2010-2021: Deal Trends, Players and Financials" report has been added to ResearchAndMarkets.com's offering.
  • The Global Respiratory Partnering 2010 to 2021 report provides comprehensive access to available deals and contract documents for over 850 respiratory deals.
  • The report takes readers through the comprehensive Respiratory disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Respiratory deals.
  • Global Respiratory Partnering 2010 to 2021 includes:
    In Global Respiratory Partnering 2010 to 2021, available deals and contracts are listed by:

RSNA: Lung Injuries from Vaping Have Characteristic Patterns on CT

Retrieved on: 
Friday, August 28, 2020
Tobacco, Electronic cigarettes, Smoking, Psychoactive drugs, Occupational diseases, Vaping-associated pulmonary injury, Hypersensitivity pneumonitis, Pneumonitis, Electronic cigarette, Lung cancer

Last year, the Centers for Disease Control and Prevention (CDC) received its first report on an illness known as electronic cigarette or vaping product use-associated lung injury (EVALI).

Key Points: 
  • Last year, the Centers for Disease Control and Prevention (CDC) received its first report on an illness known as electronic cigarette or vaping product use-associated lung injury (EVALI).
  • Dr. Gotway and colleagues classified the CT scan pattern according to several different recognized patterns.
  • That pattern was found more commonly than a CT pattern resembling subacute hypersensitivity pneumonitis, a term for the inflammation of lung tissue.
  • The Society is based in Oak Brook, Ill. ( RSNA.org )
    For patient-friendly information on lung CT, visit RadiologyInfo.org .

FDA Approves First Treatment for Group of Progressive Interstitial Lung Diseases

Retrieved on: 
Monday, March 9, 2020
Occupational diseases, Non-specific interstitial pneumonia, Interstitial lung disease, Respiratory diseases, Hypersensitivity pneumonitis, Pulmonary fibrosis, Pneumonitis, Pneumonia, Respiratory disease, RTT, Usual interstitial pneumonia, Idiopathic pulmonary fibrosis

It is the first FDA-approved treatment for this group of fibrosing lung diseases that worsen over time.

Key Points: 
  • It is the first FDA-approved treatment for this group of fibrosing lung diseases that worsen over time.
  • "Today's approval helps to fulfill an unmet treatment need, as patients with these life-threatening lung diseases have not had an approved medication until now."
  • Chronic fibrosing ILD with a progressive phenotype encompasses a group of fibrotic lung diseases caused by different underlying diseases or conditions, including autoimmune ILD, hypersensitivity pneumonitis and idiopathic nonspecific interstitial pneumonia.
  • Characteristics of chronic fibrosing ILD include lung scarring and rapid disease progression, as assessed through worsening lung function tests, symptoms and/or imaging.